Reid Hoffman Launches AI Startup, Manas AI, for Cancer Drug Discovery
LinkedIn co-founder Reid Hoffman has founded Manas AI, an AI-powered startup focused on accelerating cancer drug discovery.
Manas AI leverages its proprietary platform to identify potential drug candidates with unprecedented speed and accuracy. The company will initially prioritize breast cancer, prostate cancer, and lymphoma, expanding to other autoimmune diseases and rare conditions in the future.
"AI holds immense potential for shaping humanity. Manas AI aims to unlock its power to transform medical innovation, delivering exponential impact in treating human diseases," said Hoffman.
The startup has secured $25 million in seed funding led by General Catalyst, with support from Greylock and other investors in the life sciences and technology sectors. Hoffman has also made a personal investment.
Manas AI has forged a partnership with Microsoft to utilize its cloud computing platform. The company's co-founder is renowned cancer researcher Dr. Siddhartha Mukherjee.
"Our mission is to revolutionize drug discovery and development, saving lives," said Mukherjee. "With AI and our exceptional team, we aim to streamline and accelerate the process of delivering groundbreaking treatments."
Manas AI joins a growing number of tech companies leveraging AI for drug discovery. Google DeepMind's CEO anticipates AI-designed drugs entering clinical trials by year-end.